Tissue expression of the proteins Fas and Fas ligand in colorectal cancer and liver metastases

Journal of Gastrointestinal Cancer

Volumn 43, Issue 2, 2012, Pages 224-228

  Kykalos, Stylianos ^a,b   Mathaiou, Spuridon ^a   Karayiannakis, Anastasios J ^a   Patsouras, Dimitris ^a   Lambropoulou, Maria ^a   Simopoulos, Constantinos ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^b NONE   (Greece)

Author keywords

Apoptosis; Colon cancer; Fas FasL

Indexed keywords

FAS ANTIGEN; FAS LIGAND;

ADULT; ARTICLE; CANCER PATIENT; CANCER SURGERY; CANCER TISSUE; CLINICAL FEATURE; COLORECTAL CANCER; COLORECTAL SURGERY; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RECEPTOR UPREGULATION; RISK FACTOR; SIGNAL TRANSDUCTION; TISSUE DIFFERENTIATION;

EID: 84863873351     PISSN: 19416628     EISSN: 19416636     Source Type: Journal    
DOI: 10.1007/s12029-011-9252-6     Document Type: Article

References (20)

1. Nijhawan D, Honarpour N, Wang X. Apoptosis in neural development and disease. Annu Rev of Neurosci. 2000;23:73-87. (Pubitemid 30350038)
2. Lee WC, Yu MC, Chen MF. Prognostic impact of Fas ligand on hepatocellular carcinoma after hepatectomy. World J Surg. 2004;28(8):792-6.
3. Ohno S, Tachibana M, Shibakita M, et al. Prognostic significance of Fas and -system-associated apoptosis in gastric cancer. Ann Surg Oncol. 2000;7(10):750-7.
4. O'Connell J, Bennett MW, O'Sullivan GC, et.al. Resistance to FAS (APO-1/CD95)-mediated apoptosis and expression of Fas ligand in esophageal cancer: the Fas counterattack dis esophagus. 1999; 12 2:83-9.
5. Bernstorff WV, Glickman JN, Odze RD, et al. Fas (CD95/APO-1) and Fas ligand expression in normal pancreas and pancreatic tumors. Implications for immune privilege and immune escape. Cancer. 2002;94(10):2552-60. (Pubitemid 34478067)
6. Koomägi R, Volm M. Expression of Fas (CD95/APO-1) and Fas ligand in lung cancer, its prognostic and predictive relevance. Int J Cancer. 1999;84(3):239-43. (Pubitemid 29256748)
7. O'Connell J, Bennett MW, O'Sullivan GC, et al. Expression of Fas (CD95/APO-1) ligand by human breast cancers: significance for tumor immune privilege. Clin Diagn Lab Immunol. 1999;6 (4):457-63. (Pubitemid 29330723)
8. Reed J, Hakam A, Nicosia S, Coppola D. Significance of Fas receptor protein expression in epithelial ovarian cancer. Hum Pathol. 2005;36(9):971-6. (Pubitemid 41253382)
9. Backus HJ, Van Groeningen CJ, Vos W, Dukers DF, Bloemena E, Wouters D, et al. Differential expression of cell cycle and apoptosis related proteins in colorectal mucosa, primary colon tumours, and liver metastases. J Clin Pathol. 2002;55:206-11. (Pubitemid 34250907)
10. Belluco C, Esposito G, Bertorelle R, et al. Fas ligand is upregulated during the colorectal adenoma-carcinoma sequence. Eur J Surg Oncol. 2002;28:120-5. (Pubitemid 35023652)
11. Chopin D, Barei-Moniri R, Maille P, Le Frere-Belda MA, Muscatelli-Groux B, Merendino N, et al. Human urinary bladder transitional cell carcinomas acquire the functional Fas ligand during tumor progression. Am J Pathol. 2003;162:1139-49. (Pubitemid 36350659)
12. Korkolopoulou P, Saetta AA, Levidou G, et al. c-FLIP expression in colorectal carcinomas: association with Fas/FasL expression and prognostic implications. Histopathology. 2007 Aug;51 (2):150-6. Epub 2007 Jun 8.
13. Bennett MW, O'Connell J, Houston A, Kelly J, O'Sullivan GC, Collins JK, et al. Fas ligand upregulation is an early event in colonic carcinogenesis. J Clin Pathol. 2001;54:598-604. (Pubitemid 32756440)
14. Lambert C, Landau AM, Desbarats J. Fas-beyond death: a regenerative role for Fas in the nervous system. Apoptosis. 2003;8:551-62. (Pubitemid 37411739)
15. Houston AM, Michael-Robinson JM, Walsh MD. et al. The "Fas Counterattack" is not an active mode of tumor immune evasion in colorectal cancer with high-level microsatellite instability. Hum Pathol. 2008 Feb;39(2):243-50. Epub 2007 Oct 24.
16. Sugita J, Ohtani H, Mizoi T, et al. Close association between Fas ligand (FasL; CD95L)-positive tumor-associated macrophages and apoptotic cancer cells along invasive margin of colorectal carcinoma: a proposal on tumor-host interactions. Jpn J Cancer Res. 2002;93(3):320-8. (Pubitemid 34464369)
17. Kramer G, Erdal H, Mertens HJ, et al. Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18. Cancer Res. 2004;64:1751-6. (Pubitemid 38428698)
18. Koornstra JJ, De Jong S, Hollema H, De Vries EG, Kleibeuker JH. Changes in apoptosis during the development of colorectal cancer: a systematic review of the literature. Crit Rev Oncol Hematol. 2003;45:37-53. (Pubitemid 35449787)
19. Mann B, Gratchev A, Bohm C, Hanski ML, Foss HD, Demel G, et al. FasL is more frequent expressed in liver metastases of colorectal cancer than in matched primary carcinomas. Br J Cancer. 1999;79:1262-9. (Pubitemid 29087908)
20. Liu Z, Liu R, Qiu J, et al. Combination of human Fas (CD95/Apo-1) ligand with adriamycin significantly enhances the efficacy of antitumor response. Cell Mol Immunol. 2009;6(3):167-74.